Reforgene named a Guangzhou Future Unicorn for the third consecutive year
Recently, the Guangzhou Unicorn list was grandly released at the 2024 China Overseas Talent Exchange Conference. Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), focused on innovative R&D of gene editing medicines, was successfully selected as a "Future Unicorn" innovative enterprise. It is worth noting that Reforgene has received this honor for three consecutive years. The continued recognition is not only affirmation by the government and industry of Reforgene's innovation capability and development potential, but also highlights Guangzhou's outstanding achievements in cultivating technology innovation enterprises.
The 2024 Guangzhou Unicorn innovative enterprises list is guided by the Guangzhou Municipal Science and Technology Bureau, hosted by the Guangzhou Science and Technology Innovation Enterprises Association, jointly released by the Guangzhou Industrial Development Research Institute and the Guangzhou Science and Technology Innovation Enterprises Association, and co-organized by China Construction Bank Guangzhou Branch. It aims to deeply implement the innovation-driven development strategy, identify a group of Guangzhou "unicorn" and "potential unicorn" enterprises with strong innovation, fast growth and great development potential, cultivate growth-oriented innovative enterprises, and give play to the leading and driving role of the new economy.
This honor encourages us to continue deepening innovative R&D of gene editing medicines, accelerate the transformation of innovative achievements into clinical applications, and bring curative treatment options to patients worldwide. We will cherish this honor, keep forging ahead, promote the progress of gene editing technology, and contribute Chinese wisdom and strength to the global health cause.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.